12 Best Long Term Low Risk Stocks to Buy Right Now

Page 5 of 12

8. Pfizer Inc. (NYSE:PFE)

Number of Hedge Fund Holders: 80 

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. For the third quarter of 2024, the company reported earnings per share (EPS) of $1.06, surpassing analysts’ expectations of $0.64. Revenue for the quarter was $17.70 billion, a 31.2% increase year-over-year, exceeding the anticipated $14.92 billion. In the 2025 fiscal year, the company projects revenues between $61 and $64 billion, with operational revenue growth ranging from flat to 5% compared to 2024. This outlook includes expectations for COVID-19 product revenues to remain consistent with 2024, excluding a one-time $1.2 billion Paxlovid revenue. Investors should keep an eye on Pfizer’s $43 billion acquisition of Seagen which aims to enhance its cancer drug portfolio, focusing on antibody-drug conjugates (ADCs). The company anticipates that ADCs could contribute up to $10 billion in annual sales by 2030.

Page 5 of 12